RxSight downgraded to Hold from Buy at Stifel
Stifel downgraded RxSight (RXST) to Hold from Buy with a price target of $40, down from $65. The firm’s latest deep-dive survey of surgeons ...
Nasdaq11d
RxSight downgraded to Hold from Buy at Stifel
new Tecnis Odyssey lens “jumping off the page” in its findings and with Alcon’s (ALC) PanOptix Pro around the corner, the analyst tells investors in a research note. Stifel adds that its ...
Investing11d
Stifel downgrades RxSight stock on slowing LAL adoption projections
The analysts at Stifel highlighted that the new Tecnis Odyssey lens from Johnson & Johnson and the upcoming PanOptix Pro from Alcon (NYSE:ALC) could pose more substantial competition than ...
Investing11d
Stifel downgrades RxSight stock on slowing LAL adoption projections
The analysts at Stifel highlighted that the new Tecnis Odyssey lens from Johnson & Johnson and the upcoming PanOptix Pro from Alcon (NYSE:ALC) could pose more substantial competition than previously ...
Hosted on MSN20d
“What I Wish I’d Known About Cataract Surgery”: A Doctor Details What Patients Should Know About a Common Procedure
An expert MD reveals clear insights into cataract surgery, spotlighting the breakthroughs in treatment: "We live in a time of ...